Should we use PPAR agonists to reduce cardiovascular risk?

PPAR Research

Volumn , Issue , 2008, Pages

  Robinson, Jennifer G ^a  

^a UNIVERSITY OF IOWA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; BEZAFIBRATE; CLOFIBRATE; FENOFIBRATE; GEMFIBROZIL; GLIBENCLAMIDE; LIPID; METFORMIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PIOGLITAZONE; PLACEBO; ROSIGLITAZONE; SULFONYLUREA;

ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CARDIOVASCULAR SYSTEM; CEREBROVASCULAR DISEASE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DIABETES MELLITUS; DRUG EFFICACY; DRUG MECHANISM; DYSLIPIDEMIA; GLUCOSE METABOLISM; HEART INFARCTION; HUMAN; MICROANGIOPATHY; NON INSULIN DEPENDENT DIABETES MELLITUS; REVIEW; SIDE EFFECT; STROKE;

EID: 41149167048     PISSN: 16874757     EISSN: 16874765     Source Type: Journal    
DOI: 10.1155/2008/891425     Document Type: Review

References (77)

1. R. M. Evans evans@salk.edu G. D. Barish Y.-X. Wang PPARs and the complex journey to obesity. Journal of Nature Medicine 10 4 2004 355 361
2. B. V. Howard B. L. Rodriguez P. H. Bennett Prevention conference vi: diabetes and cardiovascular disease: writing group I: epidemiology. Circulation 105 18 2002 e132 137
3. S. M. Grundy Small LDL, atherogenic dyslipidemia, and the metabolic syndrome. Circulation 95 1 1997 1 4
4. P. Lefebvre G. Chinetti J.-C. Fruchart B. Staels bart.staels@pasteur- lille.fr Sorting out the roles of PPAR γ in energy metabolism and vascular homeostasis. Journal of Clinical Investigation 116 3 2006 571 580
5. R. K. Semple V. K. K. Chatterjee kkc1@mole.bio.cam.ac.uk S. O'Rahilly so104@medschl.cam.ac.uk PPARα and human metabolic disease. Journal of Clinical Investigation 116 3 2006 581 589
6. G. D. Barish V. A. Narkar R. M. Evans evans@salk.edu PPARδ: a dagger in the heart of the metabolic syndrome. Journal of Clinical Investigation 116 3 2006 590 597
7. Y.-X. Wang C.-H. Lee S. Tiep Peroxisome-proliferator-activated receptor delta activates fat metabolism to prevent obesity. Cell 113 2 2003 159 170
8. H. B. Rubins bloom013@tc.umn.edu S. J. Robins D. Collins Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. New England Journal of Medicine 341 6 1999 410 418
9. M. H. Frick O. Elo K. Haapa Helsinki Heart Study: Primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia.safety of treatment, changes in risk factors, and incidence of coronary heart disease. New England Journal of Medicine 317 20 1987 1237 1245
10. S. Behar D. Brunner E. Kaplinsky L. Mandelzweig M. Benderly Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: the bezafibrate infarction prevention (BIP) study. Circulation 102 1 2000 21 27
11. A. Keech R. J. Simes P. Parter Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 366 9500 2005 1849 1861
12. S. J. Robins D. Collins J. T. Wittes Relation of gemfibrozil treatment and lipid levels with major coronary events. VA-HIT: a randomized controlled trial. Journal of the American Medical Association 285 12 2001 1585 1591
13. J. G. Robinson jennifer-g-robinson@uiowa.edu B. Smith N. Maheshwari H. Schrott Pleiotropic effects of statins: benefit beyond cholesterol reduction? a meta-regression analysis. Journal of the American College of Cardiology 46 10 2005 1855 1862
14. D. J. Gordon J. L. Probstfield R. J. Garrison High-density lipoprotein cholesterol and cardiovascular disease. four prospective american studies. Circulation 79 1 89 8 15
15. A. Tenenbaum altenen@post.tau.ac.il M. Motro Michael.Motro@sheba.health. gov.il E. Z. Fisman zfisman@post.tau.ac.il Dual and pan-peroxisome proliferator-activated receptors (PPAR) co-agonism: the bezafibrate lessons. Cardiovascular Diabetology 4 2005
16. G. Steiner george.steiner@uhn.on.ca A. Hamsten J. Hosking Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the diabetes atherosclerosis intervention study, a randomised study. Lancet 357 9260 2001 905 910
17. Coronary Drug Project Clofibrate and niacin in coronary heart disease. Journal of American Medical Association 231 1975 4 360 380
18. M. Oliver A co-operative trial in the primary prevention of ischaemic heart disease using clofibrate. report from the committee of principal investigators. British Heart Journal 40 10 1978 1069 1118
19. M. H. Frick O. P. Heinonen J. K. Huttunen P. Koskinen M. Mänttäri V. Manninen Efficacy of gemfibrozil in dyslipidaemic subjects with suspected heart disease. an ancillary study in the Helsinki Heart Study frame population. Annals of Medicine 25 1 1993 41 45
20. C. Baigent A. Keech P. M. Kearney Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 366 9493 2005 1267 1278
21. L. Tenkanen leena.tenkanen@uta.fi M. Mänttäri P. T. Kovanen H. Virkkunen V. Manninen Gemfibrozil in the treatment of dyslipidemia: an 18-year mortality follow-up of the Helsinki Heart Study. Archives of Internal Medicine 166 7 2006 743 748
22. J. K. Huttunen O. P. Heinonen V. Manninen The helsinki heart study: an 8.5-year safety and mortality follow-up. Journal of Internal Medicine 235 1 1994 31 39
23. H. B. Rubins bloom013@umn.edu S. J. Robins D. Collins Diabetes, plasma insulin, and cardiovascular disease: subgroup analysis from the Department of Veterans Affairs High-density Lipoprotein Intervention Trial (VA-HIT). Archives of Internal Medicine 162 22 2002 2597 2604
24. S. Westphal sabine.westphal@medizin.uni-magdeburg.de J. Dierkes C. Luley Effects of fenofibrate and gemfibrozil on plasma homocysteine. Lancet 358 9275 2001 39 40
25. M. H. Davidson michaeldavidson@radiantresearch.com A. Armani J. M. McKenney T. A. Jacobson Safety considerations with fibrate therapy. American Journal of Cardiology 99 6, suppl. 1 2007 S3 S18
26. G. Luc Gerald.Luc@pasteur-lille.fr N. Jacob M. Bouly J.-C. Fruchart B. Staels P. Giral Fenofibrate increases homocystinemia through a PPARα-mediated mechanism. Journal of Cardiovascular Pharmacology 43 3 2004 452 453
27. O. Mayer Jr. mayerjr@lfp.cuni.cz J. Šimon L. Holubec R. Pikner I. Šubrt Fenofibrate-induced hyperhomocysteinemia may be prevented by folate co-administration. European Journal of Clinical Pharmacology 59 5-6 2003 367 371
28. S. Kaul kaul@cshs.org A. A. Zadeh P. K. Shah Homocysteine hypothesis for atherothrombotic cardiovascular disease. not validated. Journal of the American College of Cardiology 48 5 2006 914 923
29. C. Hottelart N. El Esper F. Rose J. M. Achard A. Fournier Fenofibrate increases creatininemia by increasing metabolic production of creatinine. Nephron 92 3 2002 536 541
30. S. M. Grundy J. I. Cleeman C. N. Bairey Merz Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment panel III guidelines. Circulation 110 2 2004 227 239
31. J. B. Buse jbuse@med.unc.edu Action to control cardiovascular risk in diabetes (ACCORD) trial: design and methods. American Journal of Cardiology 99 12, suppl. 1 2007 S21 S33
32. A. Keech tony@ctc.usyd.edu.au J. Simes P. Barter J. Best R. Scott M.-R. Taskinen Correction to the field study report. Lancet 368 9545 2006 1415
33. P. H. Jones jones@bcm.tmc.edu M. H. Davidson E. A. Stein Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR trial). American Journal of Cardiology 92 2 2003 152 160
34. P. H. Jones jones@bcm.tmc.edu M. H. Davidson Reporting rate of rhabdomyolysis with fenofibrate + statin versus gemfibrozil + any statin. American Journal of Cardiology 95 1 2005 120 122
35. D. J. Graham grahamd@cder.fda.gov J. A. Staffa D. Shatin Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs. Journal of the American Medical Association 292 21 2004 2585 2590
36. National Cholesterol Education Panel Third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) final report. Circulation 106 25 2002 3143 3421
37. J. G. Robinson jennifer-g-robinson@uiowa.edu N. J. Stone Antiatherosclerotic and antithrombotic effects of omega-3 fatty acids. American Journal of Cardiology 98 4, suppl. 1 2006 39 49
38. C. Wang W. S. Harris M. Chung N-3 fatty acids from fish or fish-oil supplements, but not α-linolenic acid, benefit cardiovascular disease outcomes in primary- and secondary-prevention studies: a systematic review. American Journal of Clinical Nutrition 84 1 2006 5 17
39. J. M. McKenney jmckenney@ncrinc.net M. Farnier K.-W. Lo Safety and efficacy of long-term co-administration of fenofibrate and ezetimibe in patients with mixed hyperlipidemia. Journal of the American College of Cardiology 47 8 2006 1584 1587
40. J. A. Dormandy john.dormandy@btinternet.com B. Charbonnel D. J. Eckland Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial in macroVascular Events): a randomised controlled trial. Lancet 366 9493 2005 1279 1289
41. E. Selvin S. Marinopoulos G. Berkenblit Meta-analysis: glycosylated hemoglobin and cardiovascular disease in diabetes mellitus. Annals of Internal Medicine 141 6 2004 421 431
42. J. H. Tanne FDA places "black box" warning on antidiabetes drugs. British Medical Journal 334 7606 2007 1237
43. R. W. Nesto D. Bell R. O. Bonow Thiazolidinedione use, fluid Retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. Circulation 108 23 2003 2941 2948
44. H. J. Dargie H.Dargie@bio.gla.ac.uk P. R. Hildebrandt G. A. J. Riegger A randomized, placebo-controlled trial assessing the effects of rosiglitazone on echocardiographic function and cardiac status in type 2 diabetic patients with New York Heart Association Functional Class I or II Heart Failure. Journal of the American College of Cardiology 49 16 2007 1696 1704
45. Takeda Pharmaceuticals Actos [piogltiazone hydrochloride] prescribing information. 2007, http://www.actos.com/actospro/prescribniginto.aspx
46. GlaxoSmithKline Avandia (rosiglitazone maleate) [prescribing information]. 2007, http://us.gsk.com/products/assets/us_avandia.pdf
47. S. E. Nissen nissens@ccf.org K. Wolski Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. New England Journal of Medicine 356 24 2007 2457 2471
48. B. M. Psaty C. D. Furberg Rosiglitazone and cardiovascular risk. New England Journal of Medicine 356 24 2007 2522 2524
49. S. E. Kahn skahn@u.washington.edu S. M. Haffner M. A. Heise Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. New England Journal of Medicine 355 23 2006 2427 2443
50. H. C. Gerstein S. Yusuf J. Bosch Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet 368 9541 2006 1096 1105
51. P. D. Home philip.home@newcastle.ac.uk S. J. Pocock H. Beck-Nielsen Rosiglitazone evaluated for cardiovascular outcomes - an interim analysis. New England Journal of Medicine 357 1 2007 28 38
52. R. B. Goldberg D. M. Kendall M. A. Deeg A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia. Diabetes Care 28 7 2005 1547 1554
53. A. T. McAfee andrew.mcafee@i3drugsafety.com C. Koro J. Landon N. Ziyadeh A. M. Walker Coronary heart disease outcomes in patients receiving antidiabetic agents. Pharmacoepidemiology and Drug Safety 16 7 2007 711 725
54. K. H. Kahler kristijan.kahler@novartis.com M. Rajan G. G. Rhoads Impact of oral antihyperglycemic therapy on all-cause mortality among patients with diabetes in the veterans health administration. Diabetes Care 30 7 2007 1689 1693
55. M. F. Magee michelle.f.magee@medstar.net W. L. Isley Rationale, design, and methods for Glycemic Control in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Trial. American Journal of Cardiology 97 12, suppl. 1 2006 20 30
56. C. Abraira W. Duckworth M. McCarren Design of the cooperative study on glycemic control and complications in diabetes mellitus type 2: veterans affairs diabetes trial. Journal of Diabetes and Its Complications 17 6 2003 314 322
57. M. Hanefeld hanefeld@gwtonline-zks.de N. Marx A. Pfützner Anti-inflammatory effects of pioglitazone and/or simvastatin in high cardiovascular risk patients with elevated high sensitivity C-reactive protein. the PIOSTAT study. Journal of the American College of Cardiology 49 3 2007 290 297
58. H. C. Gerstein gerstein@mcmaster.ca M. C. Riddle D. M. Kendall Glycemia treatment strategies in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. American Journal of Cardiology 99 12, suppl. 1 2007 34 43
59. T. Hampton Diabetes drugs tied to fractures in women. Journal of the American Medical Association 297 15 2007 1645
60. H. P. Koeffler Peroxisome proliferator-activated receptor γ and cancers. Clinical Cancer Research 9 1 I 2003 1 9
61. E. Erdmann erland.erdmann@uni-koeln.de J. A. Dormandy B. Charbonnel M. Massi-Benedetti I. K. Moules A. M. Skene The effect of pioglitazone on recurrent myocardial infarction in 2,445 patients with type 2 diabetes and previous myocardial infarction. results from the PROactive (PROactive 05) study. Journal of the American College of Cardiology 49 17 2007 1772 1780
62. R. Wilcox robert.wilcox@nottingham.ac.uk M.-G. Bousser D. J. Betteridge Effects of pioglitazone in patients with type 2 diabetes with or without previous stroke: Results from PROactive (PROspective pioglitAzone Clinical Trial In macroVascular Events 04). Stroke 38 3 2007 865 873
63. D. M. Nathan dnathan@partners.org J. B. Buse M. B. Davidson Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. a consensus statement from the american diabetes association and the european association for the study of diabetes. Diabetes Care 29 8 2006 1963 1972
64. C. Fiévet J.-C. Fruchart B. Staels bart.staels@pasteur-lille.fr PPARα and PPAR γ dual agonists for the treatment of type 2 diabetes and the metabolic syndrome. Current Opinion in Pharmacology 6 6 2006 606 614
65. S. E. Nissen nissens@ccf.org K. Wolski E. J. Topol Effect of muraglitazar on death and major adverse cardiovascular events in patients with type 2 diabetes mellitus. Journal of the American Medical Association 294 20 2005 2581 2586
66. D. M. Kendall C. J. Rubin P. Mohideen Improvement of glycemic control, triglycerides, and HDL cholesterol levels with muraglitazar, a dual (α/γ peroxisome proliferator-activated receptor activator, in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a double-blind, randomized, pioglitazone-comparative study. Diabetes Care 29 5 2006 1016 1023
67. G. Boden bodengh@tuhs.temple.edu C. Homko M. Mozzoli M. Zhang K. Kresge P. Cheung Combined use of rosiglitazone and fenofibrate in patients with type 2 diabetes: prevention of fluid retention. Diabetes Care 56 1 2007 248 255
68. B. Fagerberg bjorn.fagerberg@wlab.gu.se S. Edwards T. Halmos Tesaglitazar, a novel dual peroxisome proliferator-activated receptor α/γ agonist, dose-dependently improves the metabolic abnormalities associated with insulin resistance in a non-diabetic population. Diabetologia 48 9 2005 1716 1725
69. B. K. Skrumsager K. K. Nielsen M. Müller G. Pabst P. G. Drake B. Edsberg Ragaglitazar: the pharmacokinetics, pharmacodynamics, and tolerability of a novel dual PPARα and γagonist in healthy subjects and patients with type 2 diabetes. Journal of Clinical Pharmacology 43 11 2003 1244 1256
70. L. Hansen larh@novonordisk.com C. T. Ekstrøm R. T. Y. Palacios M. Anant K. Wassermann R. R. Reinhardt The Pro12Ala variant of the PPARG gene is a risk factor for peroxisome proliferator-activated receptor-γ/α agonist-induced edema in type 2 diabetic patients. Journal of Clinical Endocrinology and Metabolism 91 9 2006 3446 3450
71. H. Duez helene.duez@pasteur-lille.fr B. Lefebvre P. Poulain Regulation of human ApoA-I by gemfibrozil and fenofibrate through selective peroxisome proliferator-activated receptor α modulation. Arteriosclerosis, Thrombosis, and Vascular Biology 25 3 2005 585 591
72. H. S. Camp O. Li S. C. Wise Differential activation of peroxisome proliferator-activated receptor-γ by troglitazone and rosiglitazone. Diabetes 49 4 2000 539 547
73. F. Chang L. A. Jaber H. D. Berlie M. B. O'Connell mboconnell@wayne.edu Evolution of peroxisome proliferator-activated receptor agonists. Annals of Pharmacotherapy 41 6 2007 973 983
74. S.-Y. Park Y.-R. Cho B. N. Finck Cardiac-specific overexpression of peroxisome proliferator-activated receptor- α causes insulin resistance in heart and liver. Diabetes 54 9 2005 2514 2524
75. D. L. Sprecher dennis.l.sprecher@gsk.com C. Massien G. Pearce Triglyceride: high-density lipoprotein cholesterol effects in healthy subjects administered a peroxisome proliferator activated receptor δ agonist. Arteriosclerosis, Thrombosis, and Vascular Biology 27 2 2007 359 365
76. V. Manninen M. O. Elo M. H. Frick Lipid alterations and decline in the incidence of coronary heart disease in the helsinki heart study. Journal of the American Medical Association 260 5 1988 641 651
77. P. D. Home philip.home@newcastle.ac.uk S. J. Pocock H. Beck-Nielsen Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycaemia in Diabetes (RECORD): study design and protocol. Diabetologia 48 9 2005 1726 1735